Clinical Trials Browser

Withdrawn × INDUSTRY × onapristone × Clear all

NCT06938711 2025-04-22

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Phase 1/2 Withdrawn

Breast Neoplasms